Suppr超能文献

两种癌-睾丸基因FBXO39和TDRD4在乳腺癌组织及细胞系中的表达分析

Expression analysis of two cancer-testis genes, FBXO39 and TDRD4, in breast cancer tissues and cell lines.

作者信息

Seifi-Alan Mahnaz, Shamsi Roshanak, Ghafouri-Fard Soudeh, Mirfakhraie Reza, Zare-Abdollahi Davood, Movafagh Abolfazl, Modarressi Mohammad Hossein, Kazemi Golnesa, Geranpayeh Lobat, Najafi-Ashtiani Mitra

机构信息

Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran E-mail :

出版信息

Asian Pac J Cancer Prev. 2014 Jan;14(11):6625-9. doi: 10.7314/apjcp.2013.14.11.6625.

Abstract

Breast cancer accounts for one third of new cancer cases among women. The need for biomarkers for early detection is the stimulus to researchers to evaluate altered expression of genes in tumours. Cancer-testis (CT) genes are a group with limited expression in normal tissues except testis but up-regulation in a wide variety of cancers. We here evaluated expression of two CT genes named FBXO39 and TDRD4 in 32 invasive ductal carcinoma samples, 10 fibroadenomas and 6 normal breast tissue samples, in addition to two breast cancer cell lines, MCF-7 and MDA-MB-231, by the means of quantitative real time RT-PCR. FBXO39 showed significant up-regulation in invasive ductal carcinoma samples in comparison with normal samples. It also was expressed in both cell lines and after RHOXF1 gene knock down it was down-regulated in MCF-7 but up-regulated in the MDA-MB-231 cell line. TDRD4 was not expressed in the MCF-7 cell line and any of the tissue samples except testis. However, it was expressed in MDA-MB-231 and was up-regulated after RHOXF1 gene knock down. Our results show that FBXO39 but not TDRD4 can be used for cancer detection and if proved to be immunogenic, might be a putative candidate for breast cancer immunotherapy.

摘要

乳腺癌占女性新发癌症病例的三分之一。对早期检测生物标志物的需求促使研究人员评估肿瘤中基因表达的改变。癌-睾丸(CT)基因是一类在除睾丸外的正常组织中表达有限,但在多种癌症中上调的基因。我们在此通过定量实时逆转录聚合酶链反应,评估了两个名为FBXO39和TDRD4的CT基因在32例浸润性导管癌样本、10例纤维腺瘤和6例正常乳腺组织样本中的表达,此外还评估了它们在两种乳腺癌细胞系MCF-7和MDA-MB-231中的表达。与正常样本相比,FBXO39在浸润性导管癌样本中显示出显著上调。它在两种细胞系中均有表达,在RHOXF1基因敲低后,其在MCF-7细胞系中下调,但在MDA-MB-231细胞系中上调。TDRD4在MCF-7细胞系以及除睾丸外的任何组织样本中均未表达。然而,它在MDA-MB-231中表达,并且在RHOXF1基因敲低后上调。我们的结果表明,FBXO39而非TDRD4可用于癌症检测,如果被证明具有免疫原性,可能是乳腺癌免疫治疗的一个推定候选物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验